PF-Atlas › Clinical Trials › NCT06643091

Nintedanib Treatment in Unicentric Castleman Disease

Nintedanib · Phase 2

Registry ID
NCT06643091
Phase
Phase 2
Status
Not yet recruiting
Drug / intervention
Nintedanib
Sponsor
Assistance Publique - Hôpitaux de Paris
Start
2024-11-01

About this trial

Nintedanib is evaluated in NCT06643091, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Assistance Publique - Hôpitaux de Paris. Current status: Not yet recruiting.

View NCT06643091 on ClinicalTrials.gov →

Explore related

All Nintedanib trialsAll IPF trials

Related trials

nintedanib — NCT02606877Nintedanib — NCT02598193Nintedanib — NCT02579603Nintedanib — NCT02597933Nintedanib — NCT02999178Nintedanib — NCT02607722
Medical disclaimer. This page summarizes public trial data for NCT06643091 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.